The combination of an EGFR-TKI and MET-TKI remains effective for NSCLC patients with both EGFR mutations and MET amplification after progression to a prior EGFR-TKI, especially for patients with higher levels of MET amplification (23). The gene discussed is MET; the disease is non-small cell lung carcinoma.